Sensei Biotherapeutics, Inc. (SNSE)
Largest Insider Buys in Sector
SNSE Stock Price History Chart
SNSE Stock Performance
About Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Insider Activity of Sensei Biotherapeutics, Inc.
Over the last 12 months, insiders at Sensei Biotherapeutics, Inc. have bought $425 and sold $0 worth of Sensei Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Sensei Biotherapeutics, Inc. have bought $2.06M and sold $1.1M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Celebi John (President and CEO) — $425.
The last purchase of 500 shares for transaction amount of $425 was made by Celebi John (President and CEO) on 2023‑09‑11.
List of Insider Buy and Sell Transactions, Sensei Biotherapeutics, Inc.
| 2023-09-11 | Celebi John | President and CEO | 500 0.002% | $0.85 | $425 | -3.82% | ||
| 2023-06-01 | Sale | Apeiron Investment Group Ltd. | 10 percent owner | 955,738 3.3509% | $1.58 | $1.51M | -40.07% | |
| 2023-02-23 | Apeiron Investment Group Ltd. | 10 percent owner | 2,200 0.0071% | $1.61 | $3,539 | -36.42% | ||
| 2022-03-02 | Peyer James | 1,203 0.0037% | $3.20 | $3,850 | -49.40% | |||
| 2022-03-02 | Cambrian BioPharma Inc | 10 percent owner | 1,203 0.0037% | $3.20 | $3,850 | -49.40% | ||
| 2022-03-01 | Peyer James | 2,458 0.0082% | $3.60 | $8,849 | -51.84% | |||
| 2022-03-01 | Cambrian BioPharma Inc | 10 percent owner | 2,458 0.0082% | $3.60 | $8,849 | -51.84% | ||
| 2022-02-28 | Peyer James | 42 0.0001% | $3.60 | $151 | -52.91% | |||
| 2022-02-28 | Cambrian BioPharma Inc | 10 percent owner | 42 0.0001% | $3.60 | $151 | -52.91% | ||
| 2022-02-25 | Peyer James | 2,500 0.0079% | $3.65 | $9,125 | -54.39% | |||
| 2022-02-25 | Cambrian BioPharma Inc | 10 percent owner | 2,500 0.0079% | $3.65 | $9,125 | -54.39% | ||
| 2022-02-24 | Peyer James | 15,000 0.0483% | $3.63 | $54,450 | -53.26% | |||
| 2022-02-24 | Cambrian BioPharma Inc | 10 percent owner | 15,000 0.0483% | $3.63 | $54,450 | -53.26% | ||
| 2022-02-23 | Peyer James | 2,500 0.0082% | $3.80 | $9,500 | -54.09% | |||
| 2022-02-23 | Cambrian BioPharma Inc | 10 percent owner | 2,500 0.0082% | $3.80 | $9,500 | -54.09% | ||
| 2022-02-18 | Peyer James | 15,000 0.0473% | $3.97 | $59,550 | -56.93% | |||
| 2022-02-18 | Cambrian BioPharma Inc | 10 percent owner | 15,000 0.0473% | $3.97 | $59,550 | -56.93% | ||
| 2022-02-17 | Peyer James | 4,949 0.0164% | $4.17 | $20,637 | -56.69% | |||
| 2022-02-17 | Cambrian BioPharma Inc | 10 percent owner | 4,949 0.0164% | $4.17 | $20,637 | -56.69% | ||
| 2022-02-16 | Peyer James | 2,551 0.0083% | $4.25 | $10,842 | -57.85% |
Insider Historical Profitability
| Celebi John | President and CEO | 111311 0.4453% | $0.67 | 1 | 0 | |
| Peyer James | 5231488 20.9289% | $0.67 | 59 | 0 | <0.0001% | |
| Cambrian BioPharma Inc | 10 percent owner | 5231488 20.9289% | $0.67 | 59 | 0 | <0.0001% |
| RICKS THOMAS G | director | 341769 1.3673% | $0.67 | 2 | 0 | <0.0001% |
| Pierce Robert Hamilton | Chief Scientific Officer | 0 0% | $0.67 | 0 | 4 | |
| Apeiron Investment Group Ltd. | 10 percent owner | 0 0% | $0.67 | 1 | 1 | <0.0001% |
Institutional Investor Ownership
| Newtyn Management | $976,741.00 | 3.71 | 930,230 | -40.83% | -$673,882.31 | 0.21 | |
| The Vanguard Group | $602,536.00 | 2.29 | 573,844 | +0.03% | +$202.65 | <0.0001 | |
| Renaissance Technologies | $222,000.00 | 0.84 | 211,000 | +47.03% | +$71,010.54 | <0.0001 | |
| Geode Capital Management | $143,165.00 | 0.54 | 136,318 | 0% | +$0 | <0.0001 | |
| Bridgeway Capital Management | $118,545.00 | 0.45 | 112,900 | 0% | +$0 | <0.01 | |
| Bank of America | $95,301.00 | 0.36 | 90,763 | -0.03% | -$26.25 | <0.0001 | |
| BlackRock | $35,261.00 | 0.13 | 33,582 | -3.54% | -$1,292.55 | <0.0001 | |
| Millennium Management LLC | $34,216.00 | 0.13 | 32,587 | -14.9% | -$5,993.34 | <0.0001 | |
| Northern Trust | $27,351.00 | 0.1 | 26,049 | 0% | +$0 | <0.0001 | |
| State Street | $27,063.00 | 0.1 | 25,774 | 0% | +$0 | <0.0001 | |
| Citadel Advisors LLC | $25,058.00 | 0.1 | 23,864 | -7.51% | -$2,036.02 | <0.0001 | |
| Cresset Asset Management Llc | $20,655.00 | 0.08 | 19,671 | New | +$20,655.00 | <0.0001 | |
| Two Sigma Advisers LP | $19,950.00 | 0.08 | 19,000 | 0% | +$0 | <0.0001 | |
| Raymond James Associates | $14,700.00 | 0.06 | 14,000 | 0% | +$0 | <0.0001 | |
| Morgan Stanley | $12,830.00 | 0.05 | 12,219 | +5,479.45% | +$12,600.05 | <0.0001 | |
| Deuterium Capital Management Llc | $11,550.00 | 0.04 | 11,000 | 0% | +$0 | 0.02 | |
| Two Sigma | $10,685.00 | 0.04 | 10,176 | 0% | +$0 | <0.0001 | |
| Tower Research Capital | $7,049.00 | 0.03 | 6,713 | -20.51% | -$1,818.69 | <0.0001 | |
| Banque Cantonale Vaudoise | $4,000.00 | 0.02 | 3,900 | 0% | +$0 | <0.0001 | |
| JPMorgan Chase | $701.00 | <0.01 | 668 | 0% | +$0 | <0.0001 | |
| UBS | $146.00 | <0.01 | 139 | New | +$146.00 | <0.0001 | |
| Wells Fargo | $140.00 | <0.01 | 133 | +1.53% | +$2.10 | <0.0001 | |
| Royal Bank of Canada | $0 | <0.01 | 53 | -90.15% | -$0 | <0.0001 | |
| Qube Research & Technologies | $4.00 | <0.01 | 4 | 0% | +$0 | <0.0001 |